-
公开(公告)号：US20210113480A1
公开(公告)日：2021-04-22
申请号：US16969040
申请日：2019-02-12
发明人： Seong-Hyun HO , Su Jin PARK
摘要： The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.
-
公开(公告)号：US20230390211A1
公开(公告)日：2023-12-07
申请号：US18062252
申请日：2022-12-06
发明人： Seong-Hyun HO , Su Jin PARK
IPC分类号： A61K9/50 , A61P7/04 , A61K38/37 , A61P25/02 , A61K31/02 , A61K31/025 , A61K31/035 , A61K33/16 , A61K38/18 , A61K38/30 , A61K47/06 , A61K47/18 , A61K47/24 , A61K47/26 , A61K47/28
CPC分类号： A61K9/5015 , A61P7/04 , A61K38/37 , A61P25/02 , A61K31/02 , A61K31/025 , A61K31/035 , A61K33/16 , A61K38/1833 , A61K38/30 , A61K47/06 , A61K47/186 , A61K47/24 , A61K47/26 , A61K47/28 , A61K48/00
摘要： The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.
-
公开(公告)号：US20210163575A1
公开(公告)日：2021-06-03
申请号：US16770678
申请日：2018-12-05
发明人： Seong-Hyun HO , Su Jin PARK
IPC分类号： C07K14/755 , A61K48/00 , C12N15/85
摘要： The present disclosure relates to an expression vector that carries a polynucleotide coding for a coagulation factor VIII mutant and has increased protein expression and a pharmaceutical composition containing the expression vector for preventing or treating hemorrhagic disease or hemorrhage.
The factor VIII mutant of the present disclosure is derived by deleting a part of the B-domain (residues 784-1667) and a part of the a3 region (residues 1668-1671) in factor VIII and, as a result, an expression vector carrying a polynucleotide coding for the factor VIII mutant has remarkably increased protein expression.-
4.发明申请公开(公告)号：US20220193163A1
公开(公告)日：2022-06-23
申请号：US17605483
申请日：2020-04-24
发明人： Su Jin PARK , Seong-Hyun HO
IPC分类号： A61K36/18 , A23L33/105 , A61P17/16
摘要： The present disclosure relates to a composition for alleviating ultraviolet ray-induced skin damage or moisturizing skin, more particularly, to a composition containing an Actinidia polygama extract as an active ingredient. The composition can alleviate the reduction of skin moisture caused by ultraviolet ray-induced skin barrier damage and the resultant skin dryness, reduced skin elasticity and increased skin roughness and, as such, can be utilized as a food composition for alleviating ultraviolet ray-induced skin damage or moisturizing skin and, furthermore, as a health functional food or pharmaceutical composition, an animal feed composition, a pharmaceutical composition for animals or a cosmetic composition.
-
公开(公告)号：US20210113668A1
公开(公告)日：2021-04-22
申请号：US16969092
申请日：2019-02-12
发明人： Seong-Hyun HO , Su Jin PARK
IPC分类号： A61K38/30 , A61K9/50 , A61K31/02 , A61K33/16 , A61K31/035 , A61K31/025 , A61P25/02 , A61K47/24 , A61K47/26 , A61K47/28 , A61K47/06 , A61K47/18 , A61K38/18
摘要： The present disclosure relates to a composition for increasing the expression of a growth factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with a growth factor gene, the composition for increasing the expression of a growth factor gene of the present disclosure can increase the expression of the co-administered gene by at least 30%. Especially, when administered along with at least one gene selected from a human hepatocyte growth factor (HGF) gene, an isoform gene of the human hepatocyte growth factor and a variant gene thereof, or at least one gene selected from a human insulin-like growth factor 1 (IGF1) gene, an isoform gene of the human insulin-like growth factor 1 and a variant gene thereof, which are appropriate for the present disclosure, the composition can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.
-
-
-
-
搜索结果
5 条记录 (耗时 0.018 秒)
